Beijing Nuobot Biotech

Beijing Nuobot Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative peptide drugs for metabolic and cardiovascular diseases. The company utilizes its proprietary long-acting peptide technology and oral delivery platforms to address significant unmet medical needs in conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Its robust pipeline includes several multi-target agonists, such as GLP-1/GIP dual agonists and GLP-1/GIP/GCG triple agonists, which aim to provide superior efficacy and patient convenience. Nuobot's lead candidate, a semaglutide biosimilar, is currently in Phase 3 clinical trials in China. The company is backed by prominent venture capital firms and is positioned as a key player in the rapidly evolving Chinese incretin market.